Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-272-6138
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
OptionableNot Optionable
Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions
What is Eiger Biopharmaceuticals' stock symbol?
Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."
How were Eiger Biopharmaceuticals' earnings last quarter?
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.43. View Eiger Biopharmaceuticals' Earnings History.
When is Eiger Biopharmaceuticals' next earnings date?
What price target have analysts set for EIGR?
6 analysts have issued 12-month target prices for Eiger Biopharmaceuticals' shares. Their predictions range from $24.00 to $55.00. On average, they anticipate Eiger Biopharmaceuticals' share price to reach $34.00 in the next year. This suggests a possible upside of 146.2% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.
What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.
Has Eiger Biopharmaceuticals been receiving favorable news coverage?
Media coverage about EIGR stock has been trending very positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Eiger Biopharmaceuticals' key competitors?
Some companies that are related to Eiger Biopharmaceuticals include Audentes Therapeutics (BOLD), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Coherus Biosciences (CHRS), Novavax (NVAX), Vericel (VCEL), Acorda Therapeutics (ACOR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), Cellectis (CLLS), Twist Bioscience (TWST), NanoString Technologies (NSTG), Adaptimmune Therapeutics (ADAP) and PDL BioPharma (PDLI).
Who are Eiger Biopharmaceuticals' key executives?
Eiger Biopharmaceuticals' management team includes the folowing people:
- Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
- Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
- Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
- Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
- Mr. Sri Ryali, Chief Financial Officer
Who are Eiger Biopharmaceuticals' major shareholders?
Eiger Biopharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Interwest Venture Management Co. (6.51%). Company insiders that own Eiger Biopharmaceuticals stock include Eldon C Mayer III, Interwest Partners X Lp, Jeffrey S Glenn, Joanne Quan and Thomas John Dietz. View Institutional Ownership Trends for Eiger Biopharmaceuticals.
Which major investors are selling Eiger Biopharmaceuticals stock?
EIGR stock was sold by a variety of institutional investors in the last quarter, including Interwest Venture Management Co.. Company insiders that have sold Eiger Biopharmaceuticals company stock in the last year include Interwest Partners X Lp and Joanne Quan. View Insider Buying and Selling for Eiger Biopharmaceuticals.
How do I buy shares of Eiger Biopharmaceuticals?
Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eiger Biopharmaceuticals' stock price today?
One share of EIGR stock can currently be purchased for approximately $13.81.
How big of a company is Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals has a market capitalization of $263.70 million. The biotechnology company earns $-42,440,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis. Eiger Biopharmaceuticals employs 16 workers across the globe.
What is Eiger Biopharmaceuticals' official website?
How can I contact Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]
MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
